The effects of troglitazone on AMPK in HepG2 cells

Volume: 623-624, Pages: 49 - 57
Published: Jun 1, 2017
Abstract
AMP-activated protein kinase (AMPK) is an enzyme crucial in cellular metabolism found to be inhibited in many metabolic diseases including type 2 diabetes. Thiazolidinediones (TZDs) are a class of anti-diabetic drug known to activate AMPK through increased phosphorylation at Thr172, however there has been no research to date on whether they have any effect on inhibition of AMPK's lesser known site of inhibition, Ser485/491. HepG2 cells were...
Paper Details
Title
The effects of troglitazone on AMPK in HepG2 cells
Published Date
Jun 1, 2017
Volume
623-624
Pages
49 - 57
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.